Application of combined biomarker in preparation of product for predicting, evaluating or diagnosing hepatocellular carcinoma

The invention provides an application of a combined biomarker in preparation of a product for predicting, evaluating or diagnosing hepatocellular carcinoma, and belongs to the technical field of in vitro diagnosis, the combined biomarker comprises alpha fetoprotein (AFP) and soluble growth stimulation expression gene 2 protein (sST2). Compared with a normal group, a chronic hepatitis B group and a hepatocellular carcinoma group, the AFP level and the sST2 level are obviously increased, and the difference has statistical significance. Serum AFP and sST2 are jointly detected, so that the diagnosis efficiency of hepatocellular carcinoma can be improved, and the kit has the advantages of high sensitivity and good specificity. 本发明提供了一种联合生物标志物在制备预测、评价或诊断肝细胞癌的产品中的应用，属于体外诊断技术领域，所述联合生物标志物包括甲胎蛋白(AFP)和可溶性生长刺激表达基因2蛋白(sST2)。相比正常组以及慢性乙型肝炎组，肝细胞癌组中AFP、sST2水平均明显升高，差异具有统计学意义。将血清AFP与sST2联合检测，能提高肝细胞癌的诊断效能，具有灵敏度高、特异性好的优点。